About 400 reports

  • TOTAL SALES AS REPORTED BY AMGEN AND KHK
  • TOTAL SALES (EX-JAPAN) AS REPORTED BY AMGEN

Neupogen (filgrastim) ##.

  • Oncology
  • Asia
  • Japan
  • Amgen Inc.
  • Kyowa Hakko Kirin Co., Ltd.
  • Febrile Neutropenia - Dormant Projects
  • Febrile Neutropenia - Therapeutics Assessment

Filgrastim acts to raise the phagocytic activity of mature neutrophils.

  • Oncology
  • Therapy
  • United States
  • World
  • Coherus BioSciences, Inc.
  • PEGFILGRASTIM - DRUG PROFILE

NA : Not Available Source: Global Markets Direct Phase II - Trial Details Other Developmental Activities FILGRASTIM - DRUG PROFILE FILGRASTIM - DRUG PROFILE FILGRASTIM - DRUG PROFILE Drug Name Company/ Institute Name Licensed From Company Development Partner Product De

  • Biosimilar
  • Oncology
  • United States
  • Product Initiative
  • Coherus BioSciences, Inc.
  • Biocon Limited - Early Stage Pipeline Products
  • Biocon Limited - Pipeline by Indication, 2016
  • Oncology
  • India
  • World
  • Product Initiative
  • Biocon Limited

SANDOZ EXPECTS TO TAKE MARKET SHARE FROM AMGEN' S FILGRASTIM, WHICH HELD ##% OF THE US MARKET FOUR MONTHS AFTER THE LAUNCH OF ZARXIO.

  • Biosimilar
  • Oncology
  • World
  • Market Size
  • Remicade group
  • 7.11.2 DR. REDDY'S LABORATORIES - MAJOR BIOSIMILARS APPROVED FOR MARKETING
  • The following compounds are being studied as potential biosimilars:
  • Oncology
  • World
  • Market Size
  • Amgen Inc.
  • Biocon Limited
  • Drug Profiles
  • PEGFILGRASTIM - DRUG PROFILE

Filgrastim works by enhancing the activity of G-CSF receptors.

  • Oncology
  • Therapy
  • United States
  • World
  • Product Initiative
  • Xiamen Amoytop Biotech Co Ltd
  • CHEMOTHERAPY INDUCED NEUTROPENIA - PIPELINE BY MYCENAX BIOTECH INC, H2 2017
  • Chemotherapy
  • Oncology
  • United States
  • World
  • Product Initiative
  • Cancer Supportive Care Market, Global, Approved Indications for Neulasta, 2017
  • Cancer Supportive Care Market, Global, Approved Indications for Neupogen, 2017

In 2015, Sandoz received FDA approval for Zarxio, a biosimilar version of filgrastim for all the same indications as branded filgrastim.

  • Oncology
  • World
  • Amgen Inc.
  • Daiichi Sankyo Company
  • Eli Lilly & Co.
  • XIAMEN AMOYTOP BIOTECH CO LTD
  • CHEMOTHERAPY INDUCED NEUTROPENIA - DORMANT PROJECTS, H1 2018
  • Biotech
  • Chemotherapy
  • Oncology
  • United States
  • Product Initiative
  • OCT 25, 2017: AMGEN REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS

NEUPOGEN®(filgrastim) sales decreased ## percent driven by the impact of competition.

  • Oncology
  • Pharmaceutical
  • Therapy
  • United States
  • Amgen Inc.
  • Chemotherapy-induced neutropenia

NEUPOGEN (FILGRASTIM) Cancer pain affects a large number of individuals undergoing cancer treatment.

  • Blood Disease
  • Oncology
  • Amgen Inc.
  • Helsinn Group
  • Merck & Co., Inc.
  • Official Title
  • Clinical Trial profile. 51 Trial Title
  • Blood Disease
  • Oncology
  • World
  • Product Initiative
  • Amgen Inc.
  • Products
  • Oncology
  • Biocon Limited
  • Celltrion, Inc.
  • Hospira, Inc.
  • Mylan Inc.
  • Clinical Trial profile. 278 Trial Title
  • Clinical Trial profile. 236 Trial Title
  • Blood Disease
  • Blood Supply
  • Clinical Trial
  • Oncology
  • World
  • Target
  • PROMINENT DRUGS
  • Chemotherapy
  • Oncology
  • Therapy
  • World
  • Product Initiative
  • Branded Name
  • Monoclonal Antibody
  • Oncology
  • World
  • Market Size
  • Merck & Co., Inc.
  • CHEMOTHERAPY INDUCED NEUTROPENIA - PIPELINE BY BIOGENOMICS LTD
  • CHEMOTHERAPY INDUCED NEUTROPENIA - PIPELINE BY MYCENAX BIOTECH INC
  • Blood Disease
  • Oncology
  • United States
  • Product Initiative
  • Pfizer Inc.

filgrastim; methylprednisolone; peripheral blood stem cells; tacrolimus Northwestern University ## Oct 1999 ## Jul 2000 ## ## ## Phase I Study of CPX-##(CytarabineDaunorubicin) Liposome Injection in Patients with Advanced Hematologic Malignancies Multicenter Study of CPX-##(Cytarabine:Dauno

  • Cancer
  • Clinical Trial
  • Oncology
  • World
  • Product Initiative
  • provides a SWOT analysis of Rolontis.
  • 7.5.2.4 SWOT Analysis

TBO-Filgrastim (Granix).

  • Oncology
  • Amgen Inc.
  • BeyondSpring Pharmaceuticals Inc.
  • Helsinn Group
  • Novartis AG
  • Clinical Trial profile. 159 Trial Title
  • Clinical Trial profile. 89 Trial Title

Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients with Non-Hodgkin Lymphoma GDCT## NCT##, CASE##; NCI-2011-##; CDR##; P##CA## Oncology Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Anaplastic Large Cell Lymphoma (ALCL)

  • Clinical Trial
  • Oncology
  • United States
  • World
  • Product Initiative
  • Clinical Trial profile. 43 Trial Title
  • CLINICAL TRIAL PROFILE SNAPSHOTS

filgrastim; fludarabine; melphalan Scripps Health ## Mar 2005 ## Jan 2021 ## ## ## DNA Synthesis Inhibitor DNA Clinical Trial profile. ## Trial Title Trial Identifier Secondary ID(s) Therapy Area Indication(s) Biomarker(s) Trial Status Trial Phase Study Type Drug(s)/ Molecule(s) Sponsor(s

  • Leukemia
  • Oncology
  • World
  • Product Initiative
  • Alexion Pharmaceuticals, Inc.
  • Clinical Trial profile. 153 Trial Title

filgrastim ## cyclophosphamide ## docetaxel (piperacillin sodium + tazobactam sodium) (piperacillin + tazobactam) Total Source: GlobalData' s Pharma Intelligence Center Clinical Trials Database (*)Trials are taken for a time period of 1995 - 2017 2017 trials are taken as of August 2017 ##

  • Chemotherapy
  • Clinical Trial
  • Oncology
  • World
  • Amgen Inc.

filgrastim; ganciclovir; interferon alfa; prednisone; rituximab; sirolimus; valganciclovir; vincristine; zidovudine National Cancer Institute US NIH Intramural Research Program ## Sep 2004 ## Oct 2018 ## ## ## ## ##s Proteasome Inhibitor ##s Proteasome Official Title Trial Identifier Secondar

  • Clinical Trial
  • Monoclonal Antibody
  • Oncology
  • World
  • Product Initiative

Filgrastim in Treating Patients with Burkitt' s Lymphoma or Burkitt' s Leukemia GDCT## NCT##, U##CA##; CALGB-##; CDR## Oncology Burkitt Lymphoma, Leukemias, Lymphoma Completed Phase II Interventional allopurinol; cyclophosphamide; cytarabine; dexamethasone; doxoru

  • HIV AIDS
  • Lymphoma
  • Oncology
  • World
  • Product Initiative
  • 3. GDCT ID is the unique ID of GlobalData's Pharma Intelligence Center clinical trial database
  • Clinical Trial profile. 241 Trial Title

filgrastim; leucovorin; mesna; methotrexate; thiotepa; vincristine Nationwide Children' ' s Hospital National Cancer Institute US ## Sep 2015 ## Sep 2020 ## ## ## ##.

  • Clinical Trial
  • Oncology
  • United States
  • World
  • Product Initiative
  • 8.3 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS

One of the important milestones realized on this front was the FDA approval for Sandoz' s (Germany) filgrastim biosimilar-Zarxio (filgrastim-sndz)-for all five indications of the originator product-Neupogen-in 2015.

  • Oncology
  • Asia
  • Europe
  • World
  • Market Size

filgrastim; sargramostim Fred Hutchinson Cancer Research Center ## Mar 1995 ## Oct 1997 ## ## Clinical Trial profile. ## Trial Title Official Title Trial Identifier Secondary ID(s) Therapy Area Indication(s) Trial Status Trial Phase Study Type Drug(s)/ Molecule(s) Sponsor(s) Collaborato

  • Biological Therapy
  • Drug Discovery And Development
  • Oncology
  • World
  • Product Initiative
  • TRASTUZUMAB BIOSIMILARS, 2017
  • shows the current status of known trastuzumab biosimilars for HER2-positive breast cancer.

The FDA requires that the biosimilar INN is followed by a four letter suffix, denoting the product manufacturer name, such as filgrastim-sndz in the case of the filgrastim TABLE ##: TRASTUZUMAB BIOSIMILARS, 2017 ##. ##. ## NOMENCLATURE biosimilar by Sandoz.

  • Oncology
  • Forecast
  • Novartis AG
  • Pfizer Inc.
  • Roche Group

Filgrastim or Lenograstim or CSF##), Hematopoietic Progenitor Cell Antigen CD## (CD##)) Completed Phase II Interventional allogeneic bone marrow stem cells; allogeneic peripheral blood stem cells; anti-thymocyte globulin; autologous bone marrow derived stem cells; cyclophosphamide; cytarabin

  • Blood Disease
  • Leukemia
  • Oncology
  • Transplantation
  • Novartis AG